Quarterly EPS analysis of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Jay Anderson
May 18, 2017

The legal version of this piece can be viewed at https://transcriptdaily.com/2017/05/15/inovio-pharmaceuticals-inc-ino-lifted-to-hold-at-zacks-investment-research.html.

In recent action, Inovio Pharmaceuticals, Inc. The latest reports which are outstanding on Tuesday 16th of May state 1 analyst has a rating of "strong buy", 3 analysts "buy", 1 analysts "neutral", 0 analysts "sell" and 0 analysts "strong sell". The stock presently has a consensus rating of Buy and an average price target of $18.82. (NASDAQ:MACK) was trading at volume above average, prior 52-week high was $7.14 and plunged -39.29% over the same period, trading at a volume of 2.78 million. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 13.40% with $68.70 Million sitting short, betting on future declines.

Twitter Inc (NYSE:TWTR) have shown a low EPS growth of -13.50% in the last 5 years and has earnings growth of 26.00% yoy. The stock has 50-day moving average of $6.38 and a 200-day moving average of $7.48. The firm's market cap is $543.53 million. Analysts are forecasting earnings of $-0.27 on a per share basis this quarter.

Last time, the company shocked Wall Street by reporting EPS of $-0.31, smashing the consensus of $-0.31 per share. In contrast to the year ago quarter EPS was at -0.13.

United target Griezmann: 'I'd only leave Atleti to play for NY Knicks'
Griezmann, who has been heavily linked a move to Manchester United , refused to comment on a potential move to the Premier League. Dermot Corrigan is a Madrid-based football writer who covers La Liga and the Spain national team for ESPN FC.

Inovio Pharmaceuticals, Inc. had its "buy" rating reiterated by analysts at Stifel Nicolaus. Maxim Group reiterated a "hold" rating on shares of Inovio Pharmaceuticals in a research note on Thursday, February 23rd. If you are accessing this story on another site, it was copied illegally and reposted in violation of USA and global copyright & trademark law. Also, Director Morton Collins acquired 21,300 shares of the firm's stock in a transaction dated Monday, March 27th. The stock was sold at an average price of $6.54, for a total value of $962,557.20. Following the sale, the chief executive officer now directly owns 2,164,887 shares in the company, valued at approximately $14,158,360.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Following the acquisition, the director now directly owns 142,291 shares in the company, valued at approximately $889,318.75. The disclosure for this purchase can be found here. INO's value Change from Open was at 5.78% with a Gap of 0.00%. Bank of New York Mellon Corp boosted its stake in Inovio Pharmaceuticals by 3.6% in the first quarter.

3 number of analysts have estimated the sales of the company for the quarter ending Aug 7, 2017- Aug 11, 2017, analysts estimated mean sale target of 5.91 million while high and low sale targets are estimated at 8.53 million and 3.7 million respectively. Metropolitan Life Insurance Co. Finally, Vident Investment Advisory LLC increased its stake in Inovio Pharmaceuticals by 20.0% in the first quarter. Keybank National Association OH now owns 30,242 shares of the biopharmaceutical company's stock valued at $210,000 after buying an additional 1,950 shares in the last quarter. Bank of America Corp DE increased its stake in Inovio Pharmaceuticals by 14.6% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company's stock valued at $1,684,000 after buying an additional 2,073 shares in the last quarter.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) stock soared 5.90% to $3.77 on the closing of 05/12/2017. The company's stock has a normal trading capacity of 741.54K shares while the relative volume is 3.85. Geode Capital Management LLC increased its stake in Inovio Pharmaceuticals by 12.5% in the first quarter. Stoneridge Investment Partners LLC now owns 252,376 shares of the biopharmaceutical company's stock worth $2,352,000 after buying an additional 77,636 shares during the period. Institutional investors and hedge funds own 28.72% of the company's stock. Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Other reports by BadHub

Discuss This Article

FOLLOW OUR NEWSPAPER